JNJ Testing Key Resistance

The healthcare group continues to do well…and the recent rally has taken one big cap name from this group up to a key technical juncture: Johnson & Johnson (JNJ). Back in the fall, JNJ was able to successfully test its 200 week moving average for the third time in less than two years. Its 17% rally off those autumn lows has taken the stock back up near its all-time highs of the $150. In other words, it’s testing its “double-top” highs from 2018…which is also the top line of an ascending triangle pattern. (As you can see from the chart attached below, the bottom line of that pattern is its 200 week MA.) Therefore, if JNJ can break above the $150 level in a meaningful way, it’s going to be very, very bullish for the stock.

We do need to point out, however, that JNJ become quite overbought on both a short-term and intermediate-term basis. Of course, the same thing can be said about a lot of stocks. In fact, this could have been said about a lot of stocks over the past several weeks…and yet many of these stocks have kept on climbing. Therefore, JNJ just might be able to break-out immediately…even though it is quite overbought.

So what’s our take on the stock right now??? Well, we think the stock will probably pull-back a little bit over the near-term to work-off his overbought condition (or at least take a “breather” with a sideways move) before it breaks above the important $150 level in powerful way. However, if/when JNJ does break above that key resistance level of $150 in a meaningful way (whether now or after a breather), it’s going to be very bullish for the stock.

To see comments like these on a daily basis (and my more detailed weekend edition), please click here to subscribe to "The Maley Report" (

Matthew J. Maley

Managing Director

Chief Market Strategist

Miller Tabak + Co., LLC

Founder, The Maley Report

275 Grove St. Suite 2-400

Newton, MA 02466


Although the information contained in this report (not including disclosures contained herein) has been obtained from sources we believe to be reliable, the accuracy and completeness of such information and the opinions expressed herein cannot be guaranteed. This report is for informational purposes only and under no circumstances is it to be construed as an offer to sell, or a solicitation to buy, any security. Any recommendation contained in this report may not be appropriate for all investors. Trading options is not suitable for all investors and may involve risk of loss. Additional information is available upon request or by contacting us at Miller Tabak + Co., LLC, 200 Park Ave. Suite 1700, New York, NY 10166.

Posted to The Maley Report on Jan 22, 2020 — 8:01 AM
Comments ({[comments.length]})
Sort By:
Loading Comments
No comments. Break the ice and be the first!
Error loading comments Click here to retry
No comments found matching this filter
Want to add a comment? Take me to the new comment box!